| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-63. doi:10.3322/caac.21834
|
| [2] |
Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN[J]. Gut, 2023, 72(2): 338-44. doi:10.1136/gutjnl-2022-327736
|
| [3] |
Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(1): 10-32. doi:10.1016/j.annonc.2022.10.003
|
| [4] |
Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline[J]. J Clin Oncol, 2023, 41(3): 678-700. doi:10.1200/jco.22.01690
|
| [5] |
Benson AB, Venook AP, Adam M, et al. Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(2 D): e240029.
|
| [6] |
Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance[J]. Mol Cancer Ther, 2015, 14(8): 1767-76. doi:10.1158/1535-7163.mct-14-0636
|
| [7] |
Ma SC, Zhang JQ, Yan TH, et al. Novel strategies to reverse chemoresistance in colorectal cancer[J]. Cancer Med, 2023, 12(10): 11073-96. doi:10.1002/cam4.5594
|
| [8] |
Chen L, Yang FN, Chen S, et al. Mechanisms on chemotherapy resistance of colorectal cancer stem cells and research progress of reverse transformation: a mini-review[J]. Front Med, 2022, 9: 995882. doi:10.3389/fmed.2022.995882
|
| [9] |
Luo ZD, Wang YF, Zhao YX, et al. Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential[J]. World J Gastroenterol, 2023, 29(1): 1-18. doi:10.3748/wjg.v29.i1.1
|
| [10] |
Hashemi M, Esbati N, Rashidi M, et al. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer[J]. Transl Oncol, 2024, 40: 101846. doi:10.1016/j.tranon.2023.101846
|
| [11] |
Courneya KS, Vardy JL, O'Callaghan CJ, et al. Structured exercise after adjuvant chemotherapy for colon cancer[J]. N Engl J Med, 2025, 393(1): 13-25. doi:10.1056/NEJMoa2502760
|
| [12] |
Sadeghloo Z, Sadeghi A. Gut microbiota as a hidden modulator of chemotherapy: implications for colorectal cancer treatment[J]. Discov Oncol, 2025, 16(1): 1717. doi:10.1007/s12672-025-03574-0
|
| [13] |
Gapstur SM, Bouvard V, Nethan ST, et al. The IARC perspective on alcohol reduction or cessation and cancer risk[J]. N Engl J Med, 2023, 389(26): 2486-94. doi:10.1056/nejmsr2306723
|
| [14] |
Roshandel G, Ghasemi-Kebria F, Malekzadeh R. Colorectal cancer: epidemiology, risk factors, and prevention[J]. Cancers, 2024, 16(8): 1530. doi:10.3390/cancers16081530
|
| [15] |
Huang SY, Yu LL, Xiong FC, et al. Alcohol consumption and risk of early onset colorectal cancer: a systematic review and meta-analysis[J]. Colorectal Dis, 2025, 27(3): e70046. doi:10.1111/codi.70046
|
| [16] |
Zhou X, Wang LJ, Xiao JR, et al. Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis[J]. Int J Cancer, 2022, 151(1): 83-94. doi:10.1002/ijc.33945
|
| [17] |
Phipps AI, Shi Q, Limburg PJ, et al. Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147[J]. Int J Cancer, 2016, 139(5): 986-95. doi:10.1002/ijc.30135
|
| [18] |
Loroña NC, Himbert C, Ose J, et al. Alcohol consumption and smoking history at the time of diagnosis and the risk of colorectal cancer recurrence and mortality: results from the ColoCare study[J]. Cancer Epidemiol Biomarkers Prev, 2025, 34(1): 59-66. doi:10.1158/1055-9965.epi-24-0834
|
| [19] |
Brooks PJ, Zakhari S. Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis[J]. Environ Mol Mutagen, 2014, 55(2): 77-91. doi:10.1002/em.21824
|
| [20] |
Elshaghabee FMF, Bockelmann W, Meske D, et al. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions[J]. Front Microbiol, 2016, 7: 47. doi:10.3389/fmicb.2016.00047
|
| [21] |
Yuan J, Chen C, Cui JH, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae [J]. Cell Metab, 2019, 30(6): 1172. doi:10.1016/j.cmet.2019.11.006
|
| [22] |
Chen X, Zhang Z, Li H, et al. Endogenous ethanol produced by intestinal bacteria induces mitochondrial dysfunction in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2020, 35(11): 2009-19. doi:10.1111/jgh.15027
|
| [23] |
Bakrim S, El Hachlafi N, Khalid A, et al. Recent advances and molecular mechanisms of TGF-β signaling in colorectal cancer, with focus on bioactive compounds targeting[J]. Biomed Pharmacother, 2024, 177: 116886. doi:10.1016/j.biopha.2024.116886
|
| [24] |
Bhowmick S, Alikunju S, Abdul Muneer PM. NADPH oxidase-induced activation of transforming growth factor-beta-1 causes neuropathy by suppressing antioxidant signaling pathways in alcohol use disorder[J]. Neuropharmacology, 2022, 213: 109136. doi:10.1016/j.neuropharm.2022.109136
|
| [25] |
Zou HH, Wang S, Huang CJ, et al. Transforming growth factor-β signaling in alcohol-associated liver disease: a multicellular perspective[J]. Am J Pathol, 2026, 196(1): 50-67. doi:10.1016/j.ajpath.2025.09.017
|
| [26] |
Itatani Y, Kawada K, Sakai Y. Transforming growth factor‑β signaling pathway in colorectal cancer and its tumor microenvironment[J]. Int J Mol Sci, 2019, 20(23): 5822. doi:10.3390/ijms20235822
|
| [27] |
Waldner MJ, Neurath MF. TGFβ and the tumor microenvironment in colorectal cancer[J]. Cells, 2023, 12(8): 1139. doi:10.3390/cells12081139
|
| [28] |
Zhang MD, Zhang YY, Chen YZ, et al. TGF‑β signaling and resistance to cancer therapy[J]. Front Cell Dev Biol, 2021, 9: 786728. doi:10.3389/fcell.2021.786728
|
| [29] |
Liu SJ, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy[J]. Signal Transduct Target Ther, 2021, 6(1): 8. doi:10.1038/s41392-020-00436-9
|
| [30] |
Peng DD, Fu MY, Wang MN, et al. Targeting TGF‑β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21(1): 104. doi:10.1186/s12943-022-01569-x
|
| [31] |
O’Connell CP, Berndt SI, Chudy-Onwugaje K, et al. Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial[J]. Cancer, 2026, 132(3): e70201. doi:10.1002/cncr.70201
|
| [32] |
McNabb S, Harrison TA, Albanes D, et al. Meta-analysis of 16 studies of the association of alcohol with colorectal cancer[J]. Int J Cancer, 2020, 146(3): 861-73. doi:10.1002/ijc.32377
|
| [33] |
Chan DSM, Cariolou M, Markozannes G, et al. Post-diagnosis dietary factors, supplement use and colorectal cancer prognosis: a Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis[J]. Int J Cancer, 2024, 155(3): 445-70. doi:10.1002/ijc.34906
|
| [34] |
Mao L, Li Y, Zhao JP, et al. Transforming growth factor‑β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition[J]. Oncol Lett, 2017, 14(1): 647-54. doi:10.3892/ol.2017.6209
|
| [35] |
Yin JH, Wang L, Wang Y, et al. Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF‑β/Smad2/3 signaling pathway[J]. OncoTargets Ther, 2019, 12: 3893-903. doi:10.2147/ott.s199601
|
| [36] |
Aimo A, Spitaleri G, Nieri D, et al. Pirfenidone for idiopathic pulmonary fibrosis and beyond[J]. Card Fail Rev, 2022, 8: e12. doi:10.15420/cfr.2021.30
|
| [37] |
Paik SS, Lee JM, Ko IG, et al. Pirfenidone alleviates inflammation and fibrosis of acute respiratory distress syndrome by modulating the transforming growth factor‑β/smad signaling pathway[J]. Int J Mol Sci, 2024, 25(15): 8014. doi:10.3390/ijms25158014
|